| Name | Meropenem |
| Description | Meropenem (SM 7338) is a broad-spectrum carbapenem antibiotic administered intravenously for severe bacterial infections caused by sensitive agents. It commonly causes mild, transient aminotransferase elevations and can rarely lead to clinically apparent cholestatic liver injury. |
| Kinase Assay | Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software. |
| In vitro | Meropenem significantly increases the urinary excretion of valproate-glucuronide in rabbits. |
| In vivo | Meropenem exhibits an antibacterial spectrum similar to that of imipenem, but demonstrates slightly lower activity against Staphylococcus aureus and Enterococcus. It possesses enhanced activity against Pseudomonas aeruginosa, all Enterobacteriaceae, and Haemophilus influenzae. Meropenem's antimicrobial efficacy against Gram-negative organisms is two to four times greater than that of imipenem, and it has a broader spectrum in comparison to all other tested agents. Furthermore, Meropenem exhibits an antagonistic effect when combined with several beta-lactam antibiotics against strain-producing type I cephalosporins. It binds most effectively to the penicillin-binding proteins 2 of Escherichia coli and Pseudomonas aeruginosa, and to the penicillin-binding protein 1 of Staphylococcus aureus. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (260.78 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 5 mg/mL (13.04 mM), Sonication is recommended.
|
| Keywords | β-lactamases | β-Lactamase | SM-7338 | SM7338 | parenteral | neutropenia | Meropenem | Inhibitor | inhibit | Gram-positive | Gram-negative | DHP-1 | D-alanyl-D-alanine carboxypeptidase DacB | carbapenem | Bacterial | Antibiotic | anaerobic |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | Urethane | Sulfamethoxazole sodium | Doxycycline | EDTA copper(II) disodium salt | Isoeugenol | Dimethyl sulfoxide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Approved Drug Library | Pediatric Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Beta-Lactam Compound Library | Anti-Bacterial Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
